Zytiga (abiraterone) in combination with prednisone and ADT filed with FDA for supplemental New Drug Application in metastatic hormone na�ve prostate cancer or newly diagnosed, high-risk metastatic hormone sensitive prostate cancer.- Janssen Biotech.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest